• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oculis Holding AG

    3/11/25 4:30:05 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    6-K 1 ocs_6-k_erifrssfs_2024.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of March 2025

    (Commission File No. 001-41636)

     

     

    Oculis Holding AG

    (Translation of registrant's name into English)

     

     

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒

    Form 40-F ☐

     

     

     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    On March 11, 2025, Oculis Holding AG (the “Registrant”) issued a press release announcing its financial results for the fiscal year ended December 31, 2024. Copies of the press release, the Registrant’s 2024 IFRS consolidated financial statements and 2024 Statutory Financial Statements are furnished as Exhibits 99.1, 99.2 and 99.3, respectively, to this Report on Form 6-K.

     

     

     

    EXHIBIT INDEX

     

    Exhibit

    Description

    99.1

     

    Press Release dated March 11, 2025

    99.2

     

    IFRS consolidated financial statements as of and for the year ended December 31, 2024

    99.3

     

    Statutory Financial Statements of Oculis Holding AG for the year ended December 31, 2024

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

    OCULIS HOLDING AG

     

     

     

     

    Date: March 11, 2025

     

    By:

    /s/ Riad Sherif

     

     

     

    Chief Executive Officer

     


    Get the next $OCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

      Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

      12/5/23 8:03:01 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Oculis Holding AG with a new price target

      Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

      10/5/23 7:50:21 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Oculis Holding AG with a new price target

      BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

      6/14/23 8:10:40 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    SEC Filings

    See more
    • SEC Form S-8 filed by Oculis Holding AG

      S-8 - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:38:25 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      6/5/25 4:05:17 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/9/25 4:10:10 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care